Eli Lilly and Company (LLY) Earnings
Eli Lilly and Company is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $8.81. LLY has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +17.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $6.97 | $8.55 | +22.7% | $19.8B | +11.1% |
| Feb 4, 2026 | $6.91 | $7.54 | +9.1% | $19.3B | +7.5% |
| Oct 30, 2025 | $5.69 | $7.02 | +23.4% | $17.6B | +9.6% |
| Aug 7, 2025 | $5.60 | $6.31 | +12.7% | $15.6B | +5.8% |
| May 1, 2025 | $3.26 | $3.34 | +2.5% | $12.7B | +0.5% |
| Feb 6, 2025 | $5.03 | $5.32 | +5.8% | $13.5B | — |
| Oct 30, 2024 | $1.47 | $1.18 | -19.7% | $11.4B | -5.4% |
| Aug 8, 2024 | $2.60 | $3.92 | +50.8% | $11.3B | +13.2% |
| Apr 30, 2024 | $2.46 | $2.58 | +4.9% | $8.8B | -1.9% |
| Feb 6, 2024 | $2.22 | $2.49 | +12.2% | $9.4B | +4.7% |
| Nov 2, 2023 | $-0.08 | $0.10 | +225.0% | $9.5B | +6.1% |
| Apr 27, 2023 | $1.73 | $1.62 | -6.4% | $7.0B | -7.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 30, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Prepared Remarks covered various drug developments: ACHIEVE-4 results for G4 added to type 2 diabetes clinical profile, plan to complete U.S. submission in late Q2; Transcend P2D1 results for retatrutide showed profound A1C improvement and weight loss, next trial TRIUMPH-1 to read out this quarter; initiated Phase III programs for aloralintide in multiple indications; acquired Ventix Biosciences and licensed clasichizumab; EBLIS had durable disease control in ADLONG study and positive results in atopic dermatitis trial; TOGETHER-PSO had positive results in psoriasis and obesity; announced acquisition of Orna Therapeutics; positive top-line results from Hercabrutinib trial in CLL; initiated Phase III program for brenepatide in major depressive disorder and other neuroscience trials; acquired Colonia Therapeutics and Ajax Therapeutics; announced acquisition of Sintesa Pongsu. Dave's closing remarks mentioned progress in the quarter with revenue and earnings growth, multiple positive phase three trials, acquisitions, and new phase three programs. Mike opened Q&A session.